DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Phase 2

Recruiting

Conditions: Locally Advanced Extraskeletal Myxoid Chondrosarcoma
Metastatic Undifferentiated Pleomorphic Sarcoma
Locally Advanced Leiomyosarcoma
Locally Advanced Liposarcoma
Metastatic Soft Tissue Sarcoma
Unresectable Liposarcoma
Locally Advanced Undifferentiated Pleomorphic Sarcoma
Locally Advanced Unresectable Soft Tissue Sarcoma
Unresectable Leiomyosarcoma
Unresectable Undifferentiated Pleomorphic Sarcoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cabozantinib
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab

First Posted Date: 2023-05-01

Last Posted Date: 2025-02-28

Lead Sponsor: National Cancer Institute LAO

Target Recruit Count: 66

Registration Number: NCT05836571

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States

and more 24 locations

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Phase 2

Recruiting

Conditions: Cirrhosis
Cirrhosis, Liver
Cirrhosis Early
Cirrhosis Due to Hepatitis B
Cirrhosis Advanced
Cirrhosis Infectious
Cirrhosis Alcoholic
Cirrhosis Due to Hepatitis C

Interventions: Drug: Rosuvastatin

First Posted Date: 2023-04-27

Last Posted Date: 2025-04-29

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 256

Registration Number: NCT05832229

Locations: 🇺🇸
University of California San Diego NAFLD Research Center, La Jolla, California, United States
🇺🇸
Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸
LAC + USC Medical Center, Los Angeles, California, United States

and more 10 locations

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

Phase 2

Suspended

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Castration-Resistant Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8
Refractory Prostate Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Tuvusertib
Procedure: Ultrasound Imaging

First Posted Date: 2023-04-25

Last Posted Date: 2025-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT05828082

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States

and more 23 locations

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Phase 2

Suspended

Conditions: Recurrent Langerhans Cell Histiocytosis
Refractory Langerhans Cell Histiocytosis

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: FDG-Positron Emission Tomography and Computed Tomography Scan
Procedure: Lumbar Puncture
Procedure: Multigated Acquisition Scan
Drug: Tovorafenib

First Posted Date: 2023-04-25

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT05828069

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States

and more 98 locations

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Phase 1

Withdrawn

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Castration-Resistant Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Magrolimab
Drug: Olaparib

First Posted Date: 2023-04-11

Last Posted Date: 2024-05-02

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05807126

Locations: 🇺🇸
UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 2 locations

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Phase 1

Recruiting

Conditions: Metastatic Colorectal Carcinoma
Metastatic Malignant Solid Neoplasm
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma
Unresectable Malignant Solid Neoplasm

Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Capecitabine
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2023-04-07

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT05803382

Locations: 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
Memorial Hospital East, Shiloh, Illinois, United States

and more 19 locations

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma, B-Cell

Interventions: Biological: Anti-CD19 and anti-CD20 bicistronic CAR T- cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-04-04

Last Posted Date: 2025-02-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT05797233

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

Phase 2

Recruiting

Conditions: Respiratory Tract Diseases
Tumor Virus Infections
Pathologic Processes
Disease Attributes
Recurrence
Neoplasms
Infections
Neoplasms, Squamous Cell
Virus Diseases
Neoplasms by Histologic Type

Interventions: Drug: Bevacizumab

First Posted Date: 2023-04-04

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT05797246

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Advanced Non Small Cell Lung Cancer

Interventions: Drug: aerosolized aztreonam
Drug: aerosolized vancomycin
Drug: pembrolizumab

First Posted Date: 2023-03-21

Last Posted Date: 2025-04-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT05777603

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Phase 2

Recruiting

Conditions: Metastatic Midgut Neuroendocrine Tumor G1
Metastatic Midgut Neuroendocrine Tumor
Metastatic Midgut Neuroendocrine Tumor G2
Unresectable Midgut Neuroendocrine Tumor

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Lutetium Lu 177 Dotatate
Drug: Everolimus
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2023-03-17

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT05773274

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States

and more 25 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy